Literature DB >> 17196056

A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment.

Maurizio Fava1, Lesley M Graves, Franco Benazzi, Margaret J Scalia, Dan V Iosifescu, Jonathan E Alpert, George I Papakostas.   

Abstract

BACKGROUND: Antidepressant therapies have been associated with a variety of side effects of both physical and psychological nature. Until recently, however, the majority of the studies focusing on side effects of antidepressants have not routinely included assessment of cognitive side effects. The purpose of the present work is to examine cross-sectionally the prevalence of cognitive and physical side effects of antidepressants during long-term treatment of depression.
METHOD: Patients at least 18 years of age who were deemed responders to antidepressant therapy following at least 3 months of treatment for major depressive disorder (MDD) (diagnosed according to DSM-IV criteria) and whose MDD was considered to be in partial or full remission were eligible for inclusion in this study. Eligible patients were enrolled between January 2003 and December 2004. Study participants were administered the Harvard Department of Psychiatry/National Depression Screening Day (HANDS) scale, the Epworth Sleepiness Scale, the Brief Fatigue Inventory, the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ), and a study-specific questionnaire inquiring about the emergence of specific side effects such as apathy, fatigue, and inattentiveness.
RESULTS: 117 MDD patients (mean +/- SD age: 43.4 +/- 12.6 years; women: N = 78 [66.7%]) met criteria for response according to the HANDS (score < 9). Cognitive symptoms (apathy, inattentiveness, forgetfulness, word-finding difficulty, and mental slowing) were each reported on both the CPFQ and the study-specific questionnaire by more than 30% of the responders on antidepressants. The physical symptoms of fatigue and sleepiness/sedation were reported by over 40% of the responders on both the CPFQ and the study-specific questionnaire. A significant, positive relationship was found between the CPFQ and the severity of residual depressive symptoms as measured by the HANDS total score (F = 15.3, p = .0002).
CONCLUSION: Physical and cognitive symptoms are frequently reported by MDD patients who have responded to antidepressants and are treated in the long term with these agents. It is likely that these symptoms are both side effects of the antidepressants as well as residual symptoms of MDD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17196056     DOI: 10.4088/jcp.v67n1113

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  55 in total

Review 1.  Apathy in neuropsychiatric disease: diagnosis, pathophysiology, and treatment.

Authors:  Thomas N Chase
Journal:  Neurotox Res       Date:  2010-05-15       Impact factor: 3.911

2.  A placebo-controlled crossover study of iloperidone augmentation for residual anger and irritability in major depressive disorder.

Authors:  Dawn F Ionescu; Maurizio Fava; Daniel Ju Hyung Kim; Lee Baer; Richard C Shelton; Cristina Cusin
Journal:  Ther Adv Psychopharmacol       Date:  2016-02

Review 3.  Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms.

Authors:  Benji T Kurian; Tracy L Greer; Madhukar H Trivedi
Journal:  Expert Rev Neurother       Date:  2009-07       Impact factor: 4.618

Review 4.  Defining and measuring functional recovery from depression.

Authors:  Tracy L Greer; Benji T Kurian; Madhukar H Trivedi
Journal:  CNS Drugs       Date:  2010-04       Impact factor: 5.749

5.  Association between severity of depression and self-perceived cognitive difficulties among full-time employees.

Authors:  Carol Lawrence; Anuja Roy; Venkatesh Harikrishnan; Shawn Yu; Omar Dabbous
Journal:  Prim Care Companion CNS Disord       Date:  2013-05-30

6.  Treatment-related alteration of cortisol predicts change in neuropsychological function during acute treatment of late-life anxiety disorder.

Authors:  Eric J Lenze; David Dixon; Rose C Mantella; Peter M Dore; Carmen Andreescu; Charles F Reynolds; John W Newcomer; Meryl A Butters
Journal:  Int J Geriatr Psychiatry       Date:  2011-06-17       Impact factor: 3.485

7.  Racial and ethnic differences in treatment outcomes among adults with stimulant use disorders after a dosed exercise intervention.

Authors:  Katherine Sanchez; T L Greer; R Walker; T Carmody; C D Rethorst; M H Trivedi
Journal:  J Ethn Subst Abuse       Date:  2017-05-19       Impact factor: 1.507

8.  Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations.

Authors:  Jennifer C Felger; Li Li; Paul J Marvar; Bobbi J Woolwine; David G Harrison; Charles L Raison; Andrew H Miller
Journal:  Brain Behav Immun       Date:  2012-10-13       Impact factor: 7.217

9.  Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine.

Authors:  Huaiyu Yang; Lara Sinicropi-Yao; Sarah Chuzi; Soo Jeong Youn; Alisabet Clain; Lee Baer; Ying Chen; Patrick J McGrath; Maurizio Fava; George I Papakostas
Journal:  Ann Gen Psychiatry       Date:  2010-02-26       Impact factor: 3.455

10.  Current nosology of treatment resistant depression: a controversy resistant to revision.

Authors:  Michele Fornaro; Patricia Giosuè
Journal:  Clin Pract Epidemiol Ment Health       Date:  2010-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.